


In the Claims:

The current status of all claims is listed below and supersedes all previous lists of claims.

Please amend claims 1-3 and 11-13 as follows:

1. (currently amended) A compound of formula I, a pharmaceutically acceptable salt thereof, diastereomers, enantiomers, or mixtures thereof:



wherein

R^1 is ~~selected from~~ C_{6-10} aryl ~~and or~~ C_{2-6} heteroaryl, wherein said C_{6-10} aryl and C_{2-6} heteroaryl are optionally substituted with one or more groups selected from C_{1-6} alkyl, ~~R , $-NO_2$, $-O-C_{1-6}$ alkyl, $-OR$, $-Cl$, $-Br$, $-I$, $-F$, and $-CF_3$, $C(=O)R$, $C(=O)OH$, NH_2 , SH , NHR , NR_2 , SR , SO_3H , SO_2R , $S(=O)R$, CN , OH , $C(=O)OR$, $C(=O)NR_2$, $NRC(=O)R$, and $NRC(=O)OR$, wherein R is, independently, a hydrogen or C_{1-6} alkyl; and~~

R^2 , R^3 , R^4 and R^5 are, independently, selected from hydrogen, C_{1-6} alkyl, and C_{3-6} cycloalkyl, wherein said C_{1-6} alkyl and C_{3-6} cycloalkyl are optionally substituted with one or more groups selected from C_{1-6} alkyl, ~~R , $-NO_2$, $-OR$, $-O-C_{1-6}$ alkyl, $-Cl$, $-Br$, $-I$, $-F$, and $-CF_3$, $C(=O)R$, $C(=O)OH$, NH_2 , SH , NHR , NR_2 , SR , SO_3H , SO_2R , $S(=O)R$, CN , OH , $C(=O)OR$, $C(=O)NR_2$, $NRC(=O)R$, and $NRC(=O)OR$, wherein R is, independently, a hydrogen or C_{1-6} alkyl.~~

2. (currently amended) A compound according to claim 1, wherein

R^1 is ~~selected from~~ phenyl; pyridyl; thienyl; furyl; imidazolyl; triazolyl; pyrrolyl; thiazolyl; ~~and or~~ N-oxido-pyridyl, wherein R^1 is optionally substituted with one or more groups selected from C_{1-6} alkyl, ~~halogenated C_{1-6} alkyl~~, $-NO_2$, $-CF_3$, C_{1-6} alkoxy, chloro, fluoro, bromo, and iodo;

R^2 , R^3 , and R^4 are, independently, C_{1-3} alkyl or halogenated C_{1-3} alkyl;

R^5 is ~~selected from~~ hydrogen, C_{1-6} alkyl, ~~and or~~ C_{3-6} cycloalkyl, wherein said C_{1-6} alkyl and C_{3-6} cycloalkyl are optionally substituted with one or more groups selected from C_{1-6} alkyl, ~~halogenated C_{1-6} alkyl~~, $-NO_2$, $-CF_3$, C_{1-6} alkoxy, chloro, fluoro, bromo, and iodo.

3. (currently amended) A compound according to claim 1, wherein

R^1 is ~~selected from~~ phenyl; pyridyl; thienyl; furyl; imidazolyl; pyrrolyl; ~~and or~~ thiazolyl, wherein R^1 is optionally substituted with one or more groups selected from C_{1-6} alkyl, ~~halogenated C_{1-6} alkyl~~, $-NO_2$, $-CF_3$, C_{1-6} alkoxy, chloro, fluoro, bromo, and iodo;

R^2 , R^3 , and R^4 are, independently, C_{1-3} alkyl or halogenated C_{1-3} alkyl; and

R^5 is hydrogen.

4. (original) A compound according to claim 1, wherein

R^1 is selected from phenyl, pyridyl, thienyl, furyl, imidazolyl, pyrrolyl, and thiazolyl;

R^2 and R^3 are ethyl;

R^4 is C_{1-3} alkyl; and

R^5 is hydrogen.

5. (original) A compound according to claim 1, wherein the compound is selected from:

[3-[[4-[(diethylamino)carbonyl]phenyl][1-(2-thienylmethyl)-4-piperidinylidene]methyl]phenyl]-carbamic acid, methyl ester;

[3-[[4-[(diethylamino)carbonyl]phenyl][1-(2-furanylmethyl)-4-piperidinylidene]methyl]phenyl]-carbamic acid, methyl ester;

[3-[[4-[(diethylamino)carbonyl]phenyl][1-(phenylmethyl)-4-

piperidinylidene]methyl]phenyl]-carbamic acid, methyl ester;

methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[1-(1,3-thiazol-4-ylmethyl)piperidin-4-ylidene]methyl}phenylcarbamate;

methyl 3-{{4-[(diethylamino)carbonyl]phenyl}[1-(1,3-thiazol-5-ylmethyl)piperidin-4-ylidene]methyl}phenylcarbamate;

and pharmaceutically acceptable salts thereof.

6. (cancelled).


7. (withdrawn) A method for the therapy of pain, anxiety or functional gastrointestinal disorders, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 1.

8. (previously presented) A pharmaceutical composition comprising a compound according claim 1 and a pharmaceutically acceptable carrier.


9. (withdrawn) A method for the therapy of pain in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according claim 1.

10. (withdrawn) A method for the therapy of functional gastrointestinal disorders in a warm-blooded animal, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 1.

11. (withdrawn-currently amended) A process for preparing a compound of formula I according to claim 1, comprising:



reacting a compound of formula II with X-C(=O)-O-R⁴:



wherein


X is Cl, Br or I;

R¹ is ~~selected from~~ C₆₋₁₀aryl ~~and or~~ C₂₋₆heteroaryl, wherein said C₆₋₁₀aryl and C₂₋₆heteroaryl are optionally substituted with one or more groups selected from C₁₋₆alkyl, ~~R~~, -NO₂, ~~OR~~, -O-C₁₋₆alkyl, -Cl, -Br, -I, -F, and -CF₃, ~~C(=O)R~~, ~~C(=O)OH~~, ~~NH₂~~, ~~SH~~, ~~NHR~~,

~~NR₂, SR, SO₃H, SO₂R, S(=O)R, CN, OH, C(=O)OR, C(=O)NR₂, NRC(=O)R, and NRC(=O)OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl; and~~

R², R³, R⁴ and R⁵ are, independently, selected from hydrogen, C₁₋₆alkyl, and C₃₋₆cycloalkyl, wherein said C₁₋₆alkyl and C₃₋₆cycloalkyl are optionally substituted with one or more groups selected from C₁₋₆alkyl, ~~R~~, -NO₂, ~~OR~~, O-C₁₋₆alkyl, -Cl, -Br, -I, -F, and CF₃; ~~C(=O)R, C(=O)OH, NH₂, SH, NHR, NR₂, SR, SO₃H, SO₂R, S(=O)R, CN, OH, C(=O)OR, C(=O)NR₂, NRC(=O)R, and NRC(=O)OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl.~~

12. (currently amended) A compound of formula III:




wherein

R², R³, R⁴ and R⁵ are, independently, selected from hydrogen, C₁₋₆alkyl, and C₃₋₆cycloalkyl, wherein said C₁₋₆alkyl and C₃₋₆cycloalkyl are optionally substituted with one or more groups selected from C₁₋₆alkyl, ~~R~~, -NO₂, ~~OR~~, O-C₁₋₆alkyl, -Cl, -Br, -I, -F, and CF₃; ~~C(=O)R, C(=O)OH, NH₂, SH, NHR, NR₂, SR, SO₃H, SO₂R, S(=O)R, CN, OH, C(=O)OR, C(=O)NR₂, NRC(=O)R, and NRC(=O)OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl; and~~


R⁶ is selected from -H and -C(=O)-O-C₁₋₆alkyl.

13. (withdrawn-currently amended) A process for preparing a compound of formula I according to claim 1, comprising:



I

reacting a compound of formula IV with R^1 -CHO or R^1 CH₂-X:



IV

wherein

X is Cl, Br or I;

R^1 is ~~selected from~~ C₆₋₁₀aryl ~~and or~~ C₂₋₆heteroaryl, wherein said C₆₋₁₀aryl and C₂₋₆heteroaryl are optionally substituted with one or more groups selected from ~~-R~~, C₁₋₆alkyl, -NO₂, ~~-OR~~, -O-C₁₋₆alkyl, -Cl, -Br, -I, -F, and -CF₃, C(=O)R, C(=O)OH, NH₂, SH, NHR, ~~-NR₂~~, ~~-SR~~, ~~-SO₃H~~, ~~-SO₂R~~, ~~-S(=O)R~~, ~~-CN~~, ~~-OH~~, ~~-C(=O)OR~~, ~~-C(=O)NR₂~~, ~~-NRC(=O)R~~, and

~~NRC(=O)OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl; and~~

~~R², R³, R⁴ and R⁵ are, independently, selected from hydrogen, C₁₋₆alkyl, and C₃₋₆cycloalkyl, wherein said C₁₋₆alkyl and C₃₋₆cycloalkyl are optionally substituted with one or more groups selected from ~~R, C₁₋₆alkyl, -NO₂, -OR, -O-C₁₋₆alkyl, -Cl, -Br, -I, -F, and -CF₃, -C(=O)R, -C(=O)OH, -NH₂, -SH, -NHR, -NR₂, -SR, -SO₃H, -SO₂R, -S(=O)R, -CN, -OH, -C(=O)OR, -C(=O)NR₂, NRC(=O)R, and NRC(=O)OR, wherein R is, independently, a hydrogen or C₁₋₆alkyl.~~~~

14. (withdrawn) A method for the therapy of pain, anxiety or functional gastrointestinal disorders, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 2.

15. (withdrawn) A method for the therapy of pain, anxiety or functional gastrointestinal disorders, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 3.

16. (withdrawn) A method for the therapy of anxiety, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 1.

17. (withdrawn) A method for the therapy of anxiety, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 2.

18. (withdrawn) A method for the therapy of anxiety, comprising the step of administering to said animal in need of such therapy a therapeutically effective amount of a compound according to claim 3.

19. (previously presented) A pharmaceutical composition comprising a compound according to claim 2 and a pharmaceutically acceptable carrier.

20. (previously presented) A pharmaceutical composition comprising a compound according to claim 3 and a pharmaceutically acceptable carrier.

21. (previously presented) A pharmaceutical composition comprising a compound according to claim 5 and a pharmaceutically acceptable carrier.

22. (previously presented) A compound according to claim 12, wherein the compound is methyl 3-[{4-[(diethylamino)carbonyl]phenyl}(piperidin-4-ylidene)methyl]phenylcarbamate.